Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) is a phase 3 interventional study registered as NCT06966700 by Merck Sharp & Dohme LLC, with 2400 participants planned, started 2025-06-30 and due to reach its primary completion in 2033-03-23. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel and Doxorubicin.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin and the tag pipeline.
Shares Sacituzumab tirumotecan, Doxorubicin, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Epirubicin, Early triple-negative breast cancer, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Merck & Co. (MSD) and the tag pipeline.